EVEON contributes to microfluidic standards development by participating in the design and use of a modular R&D platform using standardized components. Work on this subject has been published in the magazine Sensors and Actuators B: Chemical.

EVEON and six French companies have sealed a unique partnership called JBT HubUp a unique solution for developing innovative medical devices.

To optimize its fluidic processes, EVEON has collaborated for several years with the laboratory LMGP to understand the causes of the aggregation during the manipulation of proteins. Work on this subject has been published in the magazine Langmuir.

A EVEON was awarded the special prize Ease of use and Patient compliance in the Best Innovation Exhibitor category at Pharmapack Europe 2017 for its Intuity® Ject device.

EVEON announces the release of its new prototype, which reconstitutes lyophilised drugs in just two steps, with no handling or contact with the product.

EVEON gave a presentation at 2016 PDA Europe Advanced Therapy Medicinal Products (ATMPs) Conference, on June 7-8, in Berlin (Germany).

EVEON gave a presentation at Bioproduction #5 Cell and Gene Therapies B4B connection, in Evry, 3-4 february 2016 

EVEON reaches a major milestone in its development by signing a new industrial partnership agreement in oncology.
The company design an innovative medical device for cancer treatment in the framework of the "CARAT" project which is aimed at developing a French network of excellence in nuclear medicine.

EVEON signed an agreement with the pharmaceutical group Advanced Accelerator Applications for a medical injection device in oncology.
EVEON's objective is to develop and produce an innovative automated injection system for the treatment of solid tumours.

EVEON was awarded, in december 2014, the 1st prize Monday evening in the Inventer Demain (Invent Tomorrow) international competition after winning the vote of an expert jury and the audience.